Novo Nordisk shares slumped on Monday after the drugmaker said the pill version of its weight-loss drug Ozempic had failed to slow the progression of Alzheimer’s disease in two large studies.
The Danish company said patients who took the drug did not see their disease progress more slowly, dashing hopes for a new use for the blockbuster diabetes drug.
